Prospective study assesses the effectiveness of eptinezumab for migraine prevention in patients with prior treatment failure, suggesting potential benefits.
The INFUSE study aims to assess the real-world effectiveness of eptinezumab for preventive treatment of migraine in patients in whom ≥1 preventive calcitonin gene-related peptide antagonist (anti-CGRP) had previously failed.
No takes yet. Share an insight, caveat, or question.
Estemalik et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: